

**Pirtobrutinib, a Highly Selective, Non-Covalent  
(Reversible) BTK Inhibitor in Previously Treated  
Mantle Cell Lymphoma: Updated Results from  
the Phase 1/2 BRUIN Study**

**Presented at: ASH ANNUAL MEETING & EXPOSITION**

**Date: December 12, 2021**

# Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study

Michael L. Wang<sup>1</sup>, Nirav N. Shah<sup>2</sup>, Alvaro J. Alencar<sup>3</sup>, James N. Gerson<sup>4</sup>, Manish R. Patel<sup>5</sup>, Bitu Fakhri<sup>6</sup>, Wojciech Jarczszak<sup>7</sup>, Xuan Tan<sup>8</sup>, Katharine Lewis<sup>8</sup>, Timothy Fenske<sup>2</sup>, Catherine C. Coombs<sup>9</sup>, Ian W. Flinn<sup>10</sup>, David J. Lewis<sup>11</sup>, Steven Le Gouill<sup>12</sup>, M. Lia Palomba<sup>13</sup>, Jennifer A. Woyach<sup>14</sup>, John M. Pagel<sup>15</sup>, Nicole Lamanna<sup>16</sup>, Jonathon B. Cohen<sup>17</sup>, Minal A. Barve<sup>18</sup>, Paolo Ghia<sup>19</sup>, Toby A. Eyre<sup>20</sup>, Pier Luigi Zinzani<sup>21</sup>, Chaitra S. Ujjan<sup>22</sup>, Youngil Koh<sup>23</sup>, Koji Izutsu<sup>24</sup>, Ewa Lech-Maranda<sup>25</sup>, Constantine S. Tam<sup>26</sup>, Suchitra Sundaram<sup>27</sup>, Ming Yin<sup>28</sup>, Binoj Nair<sup>28</sup>, Donald E. Tsai<sup>28</sup>, Minna Balbas<sup>28</sup>, Anthony R. Mato<sup>13</sup>, Chan Y. Cheah<sup>8</sup>

<sup>1</sup>Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX; <sup>2</sup>Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI; <sup>3</sup>Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL; <sup>4</sup>Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; <sup>5</sup>Florida Cancer Specialists / Sarah Cannon Research Institute, Sarasota, FL; <sup>6</sup>Division of Hematology and Oncology, University of California, San Francisco, CA; <sup>7</sup>Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland; <sup>8</sup>Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia; <sup>9</sup>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; <sup>10</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; <sup>11</sup>Plymouth Hospitals NHS Trust - Derriford Hospital, Plymouth, United Kingdom; <sup>12</sup>Service d'hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France; <sup>13</sup>Memorial Sloan Kettering Cancer Center, New York, NY; <sup>14</sup>The Ohio State University Comprehensive Cancer Center, Columbus, OH; <sup>15</sup>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA; <sup>16</sup>Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY; <sup>17</sup>Winship Cancer Institute, Emory University, Atlanta, GA; <sup>18</sup>Mary Crowley Cancer Research, Dallas, TX; <sup>19</sup>Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, MI, Italy; <sup>20</sup>Churchill Cancer Center, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; <sup>21</sup>Institute of Hematology "Seràgnoli" University of Bologna, Bologna Italy; <sup>22</sup>Fred Hutchinson Cancer Research Center; <sup>23</sup>Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; <sup>24</sup>National Cancer Center Hospital, Tokyo, Japan; <sup>25</sup>Institute of Hematology and Transfusion Medicine, Warsaw, Poland; <sup>26</sup>Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia; <sup>27</sup>Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; <sup>28</sup>Loxo Oncology at Lilly, Stamford, CT

# Presenting Author Disclosures

## Research support:

Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Elli Lilly, Molecular Templates, InnoCare, Juno, Loxo Oncology, Oncternal, Pharmacyclics, VelosBio, Janssen, Kite Pharma

## Advisory/Consultancy:


AstraZeneca, BeiGene, Epizyme, Janssen, Kite Pharma, Miltenyi Biomedicine GmbH, Bayer Healthcare, CSTone, DTRM Biopharma (Cayman) Limited, Genentech, InnoCare, Juno, Loxo Oncology, Oncternal, Pharmacyclics, VelosBio

## Honoraria/Travel support:

Acerta Pharma, Anticancer Association, AstraZeneca, BeiGene, CAHON, Chinese Medical Association, Clinical Care Options, Dava Oncology, Epizyme, Hebei Cancer Prevention Federation, Imbruvica, Imedex, Janssen, Kite Pharma, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, Newbridge Pharmaceuticals, OMI, Physicians Education Resources (PER), Scripps, The First Afflicted Hospital of Zhejiang University, BGICS


# Outcomes in MCL are Extremely Poor Following Covalent BTK Inhibitor Progression

- Covalent BTK inhibitor resistance in MCL and other lymphomas is incompletely understood<sup>1-10</sup>
- BTK C481-mutations are uncommon; bypass alterations & epigenetic changes implicated in some patients<sup>7</sup>
- *Overall survival* following covalent BTK inhibitor therapy is poor<sup>3,4,11</sup>




**Fig 1<sup>4</sup>**

Analysis of n = 114 global patients  
Median OS = 2.9 months



**Fig 2<sup>3</sup>**

Analysis of n = 31 US patients  
Median OS = 8.4 months




**Fig 3<sup>11</sup>**

Analysis of n = 108 Japanese patients  
Median OS = 5.46 months

# Pirtobrutinib is a Highly Potent and Selective Non-Covalent (Reversible) BTK Inhibitor


## Kinome selectivity<sup>1</sup>

Highly selective for BTK




## Xenograft models

*In vivo* activity similarly efficacious as ibrutinib in WT; superior in C481S



- Nanomolar potency against WT & C481-mutant BTK in cell and enzyme assays<sup>2</sup>
- >300-fold selectivity for BTK vs 370 other kinases<sup>2</sup>
- Due to reversible binding mode, BTK inhibition not impacted by intrinsic rate of BTK turnover<sup>2</sup>
- Favorable pharmacologic properties allow sustained BTK inhibition throughout dosing interval<sup>2</sup>

# Phase 1/2 BRUIN Study: Design, Eligibility and Enrollment




# Patient Characteristics

| Characteristics                                       | MCL<br>(n=134)     |
|---|--------------------|
| Median age (range), years                             | 70 (46, 88)        |
| Female / Male, n (%)                                  | 30 (22) / 104 (78) |
| Histology   |                    |
| Classic   | 108 (81)           |
| Pleomorphic/Blastoid                                  | 26 (19)            |
| ECOG PS, n (%)  |                    |
| 0   | 82 (61)            |
| 1   | 50 (37)            |
| 2   | 2 (2)              |
| Median number prior lines of systemic therapy (range) | 3 (1, 9)           |
| Prior therapy, n (%)                                  |                    |
| BTK inhibitor   | 120 (90)           |
| Anti-CD20 antibody                                    | 130 (97)           |
| Chemotherapy  | 122 (91)           |
| Stem cell transplant <sup>b</sup>                     | 30 (22)            |
| IMiD  | 23 (17)            |
| BCL2 inhibitor  | 20 (15)            |
| Proteasome inhibitor                                  | 17 (13)            |
| CAR-T   | 7 (5)              |
| PI3K inhibitor  | 5 (4)              |
| Reason discontinued prior BTKi <sup>a</sup>           |                    |
| Progressive disease                                   | 100 (83)           |
| Toxicity/Other  | 20 (17)            |

Data cutoff date of 16 July 2021. Total % may be different than the sum of the individual components due to rounding. <sup>a</sup>Calculated as percent of patients who received prior BTK inhibitor. <sup>b</sup>3 patients had both auto and allo stem cell transplants.

# Pirtobrutinib Efficacy in Mantle Cell Lymphoma



| BTK Pre-Treated MCL Patients <sup>a</sup>            |  | n=100              |
|--|--|--------------------|
| <b>Overall Response Rate<sup>b</sup>, % (95% CI)</b> |  | <b>51% (41-61)</b> |
| <b>Best Response</b>                                 |  |                    |
| CR, n (%)  |  | 25 (25)            |
| PR, n (%)  |  | 26 (26)            |
| SD, n (%)  |  | 16 (16)            |
| BTK Naive MCL Patients <sup>a</sup>                  |  | n=11               |
| <b>Overall Response Rate<sup>b</sup>, % (95% CI)</b> |  | <b>82% (48-98)</b> |
| <b>Best Response</b>                                 |  |                    |
| CR, n (%)  |  | 2 (18)             |
| PR, n (%)  |  | 7 (64)             |
| SD, n (%)  |  | 1 (9)              |


Efficacy also seen in patients with prior:

- Stem cell transplant (n=28): ORR 64% (95% CI: 44-81)
- CAR-T therapy (n=6): ORR 50% (95% CI: 12-88)

Data cutoff date of 16 July 2021. Data for 20 MCL patients are not shown in the waterfall plot due to no measurable target lesions identified by CT at baseline, discontinuation prior to first response assessment, or lack of adequate imaging in follow-up. \*Indicates patients with >100% increase in SPD. <sup>a</sup>Efficacy evaluable patients are those who had at least one post-baseline response assessment or had discontinued treatment prior to first post-baseline response assessment. <sup>b</sup>ORR includes patients with a best response of CR and PR. Response status per Lugano 2014 criteria based on investigator assessment. Total % may be different than the sum of the individual components due to rounding.



# Pirtobrutinib Duration of Response in Mantle Cell Lymphoma



- Median follow-up of 8.2 months (range, 1.0 - 27.9 months) for responding patients
- 60% (36 of 60) of responses are ongoing

# Pirtobrutinib Safety Profile

|  | All doses and patients (n=618)    |         |                 |         |                 |                          |           |
|--|-----------------------------------|---------|-----------------|---------|-----------------|--------------------------|-----------|
|  | Treatment-emergent AEs, (≥15%), % |         |                 |         |                 | Treatment-related AEs, % |           |
| Adverse Event                              | Grade 1                           | Grade 2 | Grade 3         | Grade 4 | Any Grade       | Grades 3/4               | Any Grade |
| Fatigue                                    | 13%                               | 8%      | 1%              | -       | 23%             | 1%                       | 9%        |
| Diarrhea                                   | 15%                               | 4%      | <1%             | <1%     | 19%             | <1%                      | 8%        |
| Neutropenia <sup>a</sup>                   | 1%                                | 2%      | 8%              | 6%      | 18%             | 8%                       | 10%       |
| Contusion                                  | 15%                               | 2%      | -               | -       | 17%             | -                        | 12%       |
| <b>AEs of special interest<sup>b</sup></b> |                                   |         |                 |         |                 |                          |           |
| Bruising <sup>c</sup>                      | 20%                               | 2%      | -               | -       | 22%             | -                        | 15%       |
| Rash <sup>d</sup>                          | 9%                                | 2%      | <1%             | -       | 11%             | <1%                      | 5%        |
| Arthralgia                                 | 8%                                | 3%      | <1%             | -       | 11%             | -                        | 3%        |
| Hemorrhage <sup>e</sup>                    | 5%                                | 2%      | 1% <sup>g</sup> | -       | 8%              | <1%                      | 2%        |
| Hypertension                               | 1%                                | 4%      | 2%              | -       | 7%              | <1%                      | 2%        |
| Atrial fibrillation/flutter <sup>f</sup>   | -                                 | 1%      | <1%             | <1%     | 2% <sup>h</sup> | -                        | <1%       |

**No DLTs reported and MTD not reached**

**96% of patients received ≥1 pirtobrutinib dose at or above RP2D of 200 mg daily**  
**1% (n=6) of patients permanently discontinued due to treatment-related AEs**

Data cutoff date of 16 July 2021. Total % may be different than the sum of the individual components due to rounding. <sup>a</sup>Aggregate of neutropenia and neutrophil count decreased. <sup>b</sup>AEs of special interest are those that were previously associated with covalent BTK inhibitors. <sup>c</sup>Aggregate of contusion, petechiae, ecchymosis, and increased tendency to bruise. <sup>d</sup>Aggregate of all preferred terms including rash. <sup>e</sup>Aggregate of all preferred terms including hematoma or hemorrhage. <sup>f</sup>Aggregate of atrial fibrillation and atrial flutter. <sup>g</sup>Represents 6 events (all grade 3), including 2 cases of post-operative bleeding, 1 case each of GI hemorrhage in the setting of sepsis, NSAID use, chronic peptic ulcer disease, and one case of subarachnoid hemorrhage in setting of traumatic bike accident. <sup>h</sup>Of 10 total afib/aflutter TEAEs, 3 occurred in patients with a prior medical history of atrial fibrillation, 2 in patients presenting with concurrent systemic infection, and 2 in patients with both.

## Conclusions

- Pirtobrutinib demonstrates promising efficacy in MCL patients previously treated with BTK inhibitors, a population with extremely poor outcomes
- Favorable safety and tolerability are consistent with the design of pirtobrutinib as a highly selective and non-covalent (reversible) BTK inhibitor
- A randomized, global, phase 3 trial comparing pirtobrutinib with investigator's choice of covalent BTK inhibitors in BTK naïve relapsed MCL is ongoing (BRUIN MCL-321; NCT04662255)

# Acknowledgements

- BRUIN trial patients, their families and caregivers
- BRUIN trial investigators and study staff
- Medical writing was supported by Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company

